<ul><li>THL Partners has acquired a majority equity stake in Red Nucleus, a provider of specialized services to life sciences companies.</li><li>Red Nucleus offers learning and development services for pharmaceutical sales teams, clinical staff, and healthcare professionals.</li><li>The company also provides support in medical and scientific communications, market access, and commercialization strategies for pharmaceutical companies.</li><li>Mike Menta has been appointed as the new CEO of Red Nucleus, with Ian Kelly assuming the role of Chief Relationship Officer and Vice Chairman of the Board of Directors.</li></ul>

Red Nucleus Turns Green Following THL Acquisition

Discover more